Nuclera: Biotech Company Expands Series C to $87 Million

British biotech company Nuclera has increased its Series C funding by $12 million, bringing the total to $87 million. The round was led by Elevage Medical Technologies and Jonathan Milner, with existing investors including the British Business Bank and GK Goh participating again.

The fresh capital will flow into the further development of the eProtein Discovery System, which will enable the complete manufacturing, purification, and binding testing of antibodies in the future. With this, Nuclera positions itself in one of the fastest-growing areas of biologics research, which increasingly relies on AI-driven workflows and high-quality datasets.

The latest expansion is a strategic step toward AI-powered protein engineering. Researchers will soon be able to perform complete end-to-end workflows for antibodies on an integrated high-throughput system. The technology is designed to identify proteins with the best chances of success early on. This saves time, reduces costs, and significantly decreases uncertainty in expression and purification.

Global Expansion

Since completing the original Series C funding in 2024, Nuclera has taken several development steps. The company integrated a workflow for membrane proteins – one of the most challenging protein classes – and expanded its global presence in APAC and the Middle East.

CEO and co-founder Dr. Michael Chen explains: “This funding underscores our growing momentum. (…) Scientists increasingly need scalable, high-quality datasets to drive AI models in biologics discovery. We are positioning Nuclera as a foundational platform for the future of protein and antibody development, ultimately to accelerate timelines for therapeutic discovery.”

Investors Emphasize Further Development

Dr. Michael Wasserman, COO at Elevage Medical Technologies, emphasizes the progress: “Since our initial investment, Nuclera has made significant advances in expanding the capabilities, adoption, and global reach of the eProtein Discovery Platform.” Dr. Jonathan Milner, Chairman of the Nuclera Board of Directors, adds: “Nuclera solves one of the most pressing bottlenecks in biologics discovery—the slow, fragmented, and resource-intensive process of synthesizing complete antibodies.”